title: Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
abstract: Enhancing the effector function by optimizing the interaction between Fc and Fcγ receptor (FcγR) is a promising approach to enhance the potency of anticancer monoclonal antibodies (mAbs). To date, a variety of Fc engineering approaches to modulate the interaction have been reported, such as afucosylation in the heavy chain Fc region or symmetrically introducing amino acid substitutions into the region, and there is still room to improve FcγR binding and thermal stability of the CH2 domain with these approaches. Recently, we have reported that asymmetric Fc engineering, which introduces different substitutions into each Fc region of heavy chain, can further improve the FcγR binding while maintaining the thermal stability of the CH2 domain by fine-tuning the asymmetric interface between the Fc domain and FcγR. However, the structural mechanism by which the asymmetrically engineered Fc improved FcγR binding remained unclear. In order to elucidate the mechanism, we solved the crystal structure of a novel asymmetrically engineered Fc, asym-mAb23, in complex with FcγRIIIa. Asym-mAb23 has enhanced binding affinity for both FcγRIIIa and FcγRIIa at the highest level of previously reported Fc variants. The structural analysis reveals the features of the asymmetrically engineered Fc in comparison with symmetric Fc and how each asymmetrically introduced substitution contributes to the improved interaction between asym-mAb23 and FcγRIIIa. This crystal structure could be utilized to enable us to design a more potent asymmetric Fc.
authors: Research Division, Chugai Pharmaceutical Co., Ltd., Japan.
authors: F
authors: F
authors: Mimoto
authors: Research Division, Chugai Pharmaceutical Co., Ltd., Japan.
authors: S
authors: S
authors: Kadono
authors: Research Division, Chugai Pharmaceutical Co., Ltd., Japan.
authors: H
authors: H
authors: Katada
authors: Research Division, Chugai Pharmaceutical Co., Ltd., Japan. Electronic address: igawatmy@chugai-pharm.co.jp.
authors: T
authors: T
authors: Igawa
authors: Research Division, Chugai Pharmaceutical Co., Ltd., Japan.
authors: T
authors: T
authors: Kamikawa
authors: Research Division, Chugai Pharmaceutical Co., Ltd., Japan.
authors: K
authors: K
authors: Hattori
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology*; D000915:Antibody Affinity; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D018360:Crystallography, X-Ray; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000737:chemistry / Q000276:immunology / Q000648:ultrastructure*; D011485:Protein Binding / Q000235:genetics / Q000276:immunology; D015202:Protein Engineering; D017452:Receptors, IgG / Q000276:immunology*; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; C496124:FCGR3A protein, human; C080568:Fc gamma receptor IIA; D007141:Immunoglobulin Fc Fragments; D017452:Receptors, IgG; D011994:Recombinant Proteins
keywords: A/I ratio; ADCC; ADCP; Effector function; Fc engineering; Fcγ receptor; FcγR; FcγR interactions; PBMC; PDB; Protein Data Bank; SPR; X-ray structure; a novel asymmetrically engineered Fc; activating FcγR binding to inhibitory FcγR binding; antibody-dependent cell-mediated cytotoxicity; antibody-dependent cell-mediated phagocytosis; asym-mAb23; mAb; monoclonal antibody; peripheral blood mononuclear cells; rms; root-mean-square; surface plasmon resonance